Compare Ascendis Pharma A/S (ASND) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Zillow Group Inc Class A — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Zillow Group Inc Class A trades at $32.38 (market cap $7.36B). The key difference: Ascendis Pharma A/S is far larger — about 2.4× Zillow Group Inc Class A's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| ASND | ZG | |
|---|---|---|
Market Cap | $17.74B | $7.36B |
Sector | Health | Media |
52-Week High | $277.18 | $86.76 |
52-Week Low | $163.32 | $29.14 |
Enterprise Value | $18.11B | $7.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Zillow Group (ZG) trades at $32.00, down 3.64% on the day, with a neutral technical signal and mixed earnings history. The company reported a return to profitability in 2025 with net income of $23 million, though valuation ratios like a P/E of 128 remain elevated. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautiously optimistic given analyst consensus targets near $57.80, but risks from litigation and competitive pressures in the real estate tech sector warrant attention. Revenue growth and execution on profitability targets are key catalysts for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
